Colorectal Cancer (CRC) is a major public health problem and is the fourth leading cause of cancer death worldwide. It is the third most common cancer among men and the second most common in women. The CRC Asia-Pacific market will be valued at $7.9 billion in 2024, growing from $5.3 billion in 2017 at a CAGR of 6%.
Over half of the incident cases of colorectal cancer (CRC) are diagnosed in patients over the age of 50. The percentage of people over 50 in 2017 and 2015 was 46.3% and 45.5% in Japan; 30.2% and 28.5% in China; 18.7% and 18% in India; 34.4% and 33.8% in Australia; and 36.4% and 34.7% in South Korea.
“Growing awareness of the disease and associated risk factors together with the availability of free testing services for CRC patients will increase early diagnosis and the treatment-receiving population, including targeted treatment, driving demand and contributing to market growth. Increasing affordability and healthcare access in India and China are also likely to contribute to the growth of the treatment-receiving pool significantly.”
REQUEST A SAMPLE REPORT:
• Aging Population to Increase Disease Prevalence
• Immune Checkpoint Inhibitors Set to Have a Significant Impact on the CRC Market
• Biomarker-Driven Strategies to Add Complexity to the CRC Treatment Algorithm
• Increasing Diagnosis of Mutation Status and Early Diagnosis
• Roche’s Avastin to Remain the Leader of the CRC Space despite the Launch of Bevacizumab Biosimilars
• High Unmet Need Remains for Neoadjuvant/Adjuvant Treatments to Improve Cure Rates in Early-Stage Resectable CRC Patients
Colorectal cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. The five-year prevalence population for CRC in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growing elderly population and increasingly Westernized lifestyles.
CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options.
The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations. The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies.
In the current market, RAS-wild-type and RAS-mutant patients can be treated with angiogenesis inhibitors such as Avastin, Cyramza and Zaltrap, while patients with RAS- or KRAS-wild-type mutations can be prescribed EGFR-targeted therapies such as Erbitux and Vectibix. However, significant unmet need remains for products that can treat BRAF-mutant CRC patients.
A therapy that targets mutant BRAF – encorafenib plus binimetinib – is being developed in the pipeline.
– The CRC Asia-Pacific market will be valued at $7.9 billion in 2024, growing from $5.3 billion in 2017 at a CAGR of 6%.
– How will immune checkpoint inhibitors such as Keytruda and Opdivo contribute to growth?
– What effect will patent expirations of currently branded therapies have on market value?
– The CRC pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.
– What are the common targets and mechanisms of action of pipeline therapies?
– Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
– What implications will the increased focus on targeted therapies have on the future of CRC treatment?
– Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
– How have the late-stage therapies performed in clinical trials?
– How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
– The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
– How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
– How could changes in risk factors such as population age, obesity and lifestyle influence the market?
– Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $1 billion.
– How do deal frequency and value compare between target families and molecule types?
– What were the terms and conditions of key licensing deals?
ASK SPECIFIC QUERIES ABOUT THIS REPORT:
Reasons to buy
– Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
– Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
– Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
– Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
– Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
– Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.
GET A COPY OF THIS REPORT, AVAILABLE IN PDF FORMAT:
Get in touch with us:
Ritesh Tiwari, Director